Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888252 | 1.00 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1CPDE2A | |
| SCHEMBL5888109 | 0.90 | PDE5A (0.48) | PDE5A | |
| SCHEMBL5888115 | 0.90 | PDE5A (0.48) | PDE5A | |
| SCHEMBL5888368 | 0.86 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5888373 | 0.86 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5888250 | 0.77 | KDM4E (0.46) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL5888000 | 0.76 | PDE5A (0.55) | PDE5A | |
| SCHEMBL5888009 | 0.76 | PDE5A (0.55) | PDE5A | |
| SCHEMBL5888019 | 0.76 | PDE5A (0.54) | PDE5A | |
| SCHEMBL5888012 | 0.76 | PDE5A (0.54) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078522-B2 | Pyridopyrimidine or naphthyridine derivative | TANABE SEIYAKU CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20050101615-A1 | Pyridopyrimidine or naphthyridine derivative | TANABE SEIYAKU CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1364950-A1 | PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101615-A1 | Pyridopyrimidine or naphthyridine derivative | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE1A 56/4885PDE1B 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.